China's AI pharma sector converges on policy, capital, and clinical milestone
Three simultaneous developments — a new Five-Year Plan, a $2.9 billion Series A record, and the world's first AI-designed drug entering Phase III — mark a structural shift in China's pharmaceutical industry. CITIC Securities assessed 2026 as the most commercially certain year yet for AI healthcare.
3 MIN READ · 29 SEP
Photo: Wikimedia CommonsPhoto: King of Hearts, CC BY-SA 4.0 / Wikimedia Commons
Subscriber Content
Subscribe to read the full analysis
Subscribe to read everything on GATE86
Already a subscriber? Log in
Follow this story
Useful?
Next in Today's signals
INDUSTRY · MOBILITY & EV
CATL and NIO pursue rival strategies to control China's battery-swapping market
4 MIN READ · 3 NOV
Related
INDUSTRY · BIOTECH & HEALTH
Beijing Institute of Brain Science and Brain-Inspired Intelligence launches three national BCI major projects
POLICY · AI & DIGITAL
SAMR releases first AI standardisation framework for China's steel sector
POLICY · AI & DIGITAL
